SCHEMBL6588596

SCHEMBL6588596

O=C(Nc1ccc(F)cc1F)c1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.77
RAB9A P51151 7/20 0.66
NPC1 O15118 6/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
GAA P10253 1/20 0.66
MAPT P10636 1/20 0.64
HTT P42858 1/20 0.64
POLB P06746 1/20 0.63
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
TP53 P04637 1/20 0.59
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2C19 P33261 1/20 0.58
HPGD P15428 1/20 0.58
ABCB1 P08183 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30369924 1.00 HDAC1 (0.77) HDAC1RAB9ANPC1SMN1; SMN2GAA
Hydrochloric Acid SCHEMBL29693057 0.98 HDAC1 (0.74) HDAC1RAB9ANPC1SMN1; SMN2GAA
SCHEMBL30739586 0.89 HDAC1 (0.75) HDAC1RAB9ANPC1SMN1; SMN2GAA
SCHEMBL30739990 0.88 RAB9A (0.72) HDAC1RAB9ANPC1SMN1; SMN2GAA
SCHEMBL29903248 0.87 HDAC1 (1.00) HDAC1MEN1KMT2A
SCHEMBL15553332 0.87 HDAC1 (1.00) HDAC1MEN1KMT2A
SCHEMBL30370145 0.86 HDAC1 (0.71) HDAC1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL23273772 0.85 HDAC1 (0.69) HDAC1RAB9ANPC1MAPTPOLB
SCHEMBL24769824 0.85 EPHX1 (0.57) HDAC1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL19392337 0.83 NPC1 (0.71) HDAC1RAB9ANPC1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017197088-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS PHARMAKEA, INC. (US) 2017-11-16 WO disclosed
EP-3160465-A1 USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY The Board of Trustees of the Leland Stanford Junior University (US) 2017-05-03 EP disclosed
WO-2015200358-A1 USE OF SMALL MOLECULES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE TOXICITY THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-12-30 WO disclosed
EP-1379234-A1 HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF Novartis AG (CH) 2004-01-14 EP disclosed
WO-2002076447-A1 HALLOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF NOVARTIS AG (CH) 2002-10-03 WO disclosed
EP-0818439-B1 Imide derivatives NISSHIN FLOUR MILLING CO (JP) 1999-10-13 EP disclosed
US-5847123-A Imide derivatives for inhibiting the production of interleukin-1β and the production of tumor necrosis factor α NISSHIN FLOUR MILLING CO., LTD. (JP) 1998-12-08 US disclosed
EP-0818439-A2 Imide derivatives NISSHIN FLOUR MILLING CO., LTD. (JP) 1998-01-14 EP disclosed